Department of Medical Laboratory Science, Kenyatta University, Kenya.
Department of Animal Science, Kenyatta University, Kenya.
Biomed Res Int. 2022 Sep 17;2022:1930102. doi: 10.1155/2022/1930102. eCollection 2022.
Cervical cancer is a leading cause of mortality among women globally. Approaches to reduce cervical cancer incidence and mortality are "screen-and-treat," where positive primary test only is used in the treatment and "screen, triage and treat," where treatment is based on positive primary and triage tests with/without histological analysis.
To determine cervical screening outcomes among HIV-infected and noninfected women using VIA, Pap smear, and HPV-PCR cervical screening methods and to determine the sensitivity, specificity, PPV and NPV of VIA, Pap smear, and HPV-PCR as primary test and sequential triage based on abnormal histopathology among HIV-infected and noninfected women. . This was a comparative cross-sectional study where women aged 18-46 years women underwent cervical screening and colposcopy-biopsy test as a positive-confirmatory test in the Referral Hospitals of Eastern Kenya.
A total of 317 (HIV negative: 156/317 (49.2%) and HIV positive: 161/317 (50.8%)) women were enrolled. Of these 81/317 (25.6%), 84/317 (26.5%), 96/317 (30.2%), and 78/122 (63.9%) participants had VIA, HPV DNA-PCR, Pap smear, and cervical histology positive results, respectively; average: 27.4% (HIV positive: 21.5%; HIV negative: 5.9%). Majority of women with LSIL [17/317 (5.4%)], HSIL [22/317 (6.9%)], invasive cancer [5/317 (1.6%)], cervicitis [45/317 (14.2%], and candidiasis 47/317 (14.8%) were HIV-infected ( < 0.001). 78/317 (24.6%) participants had positive histology test [ASCUS: 34/317 (10.7%) CIN1:17/317 (5.3%), CIN2: 16/317 (5.0%), CIN3:6/317 (1.9%), and ICC: 5/317 (1.6%)] ( > 0.001). A higher primary diagnostic accuracy was established by HPV DNA-PCR (sensitivity: 95.5%; specificity: 92.6%) than Pap smear and VIA test while in triage testing, high sensitivity was obtained by HPV DNA-PCR parallel testing with VIA test (92.6%) and Pap smear test (92.7%) and VIA cotesting with Pap smear (99.9%). HIV-infected women had increased specificity and reduced sensitivity and diagnostic accuracy by both primary and triage testing approaches. . Abnormal cervical screening outcome was high among HIV-infected than noninfected women. HIV-infected women had significantly high cases of cervical neoplastic changes. The diagnostic value of primary tests increased upon concurrent testing with other test methods hence reducing the number of women who would have been referred for biopsy.
High sensitivity and specificity in detection of CIN+ were established among HIV-infected than HIV noninfected women by HPV DNA-PCR and Pap smear than VIA test. HPV DNA-PCR test and Pap smear are more accurate in primary and sequential triage cervical screening based on abnormal histopathology outcomes among HIV-infected than noninfected women.
宫颈癌是全球女性死亡的主要原因之一。减少宫颈癌发病率和死亡率的方法有“筛查和治疗”,仅对阳性初筛进行治疗,以及“筛查、分流和治疗”,根据阳性初筛和分流试验结果并结合/不结合组织学分析进行治疗。
通过阴道镜检查、巴氏涂片和 HPV-PCR 宫颈筛查方法,确定 HIV 感染和未感染妇女的宫颈筛查结果,并确定阴道镜检查、巴氏涂片和 HPV-PCR 在 HIV 感染和未感染妇女中的敏感性、特异性、PPV 和 NPV,作为初筛和基于异常组织病理学的连续分流的依据。本研究为一项比较性横断面研究,东肯尼亚转诊医院招募了年龄在 18-46 岁之间的女性,进行宫颈筛查和阴道镜活检检测,作为阳性确认检测。
共纳入 317 名女性(HIV 阴性:156/317(49.2%)和 HIV 阳性:161/317(50.8%))。其中 81/317(25.6%)、84/317(26.5%)、96/317(30.2%)和 78/122(63.9%)的参与者分别有阴道镜检查、HPV DNA-PCR、巴氏涂片和宫颈组织学阳性结果,平均阳性率为 27.4%(HIV 阳性:21.5%;HIV 阴性:5.9%)。大多数低度鳞状上皮内病变(LSIL)[17/317(5.4%)]、高度鳞状上皮内病变(HSIL)[22/317(6.9%)]、浸润性癌[5/317(1.6%)]、宫颈炎[45/317(14.2%)]和念珠菌病[47/317(14.8%)]患者为 HIV 感染(<0.001)。78/317(24.6%)的参与者有阳性组织学检测结果[ASCUS:34/317(10.7%)、CIN1:17/317(5.3%)、CIN2:16/317(5.0%)、CIN3:6/317(1.9%)和 ICC:5/317(1.6%)](>0.001)。HPV DNA-PCR(敏感性:95.5%;特异性:92.6%)比巴氏涂片和阴道镜检查具有更高的初筛诊断准确性,而在分流检测中,HPV DNA-PCR 平行检测与阴道镜检查(92.6%)和巴氏涂片检查(92.7%)以及阴道镜检查和巴氏涂片联合检测(99.9%)具有较高的敏感性。HIV 感染妇女的初筛和分流检测方法的特异性增加,敏感性和诊断准确性降低。HIV 感染妇女的宫颈肿瘤病变明显较高。HPV DNA-PCR 和巴氏涂片检测在检测 CIN+方面的敏感性和特异性均高于阴道镜检查。HPV DNA-PCR 检测和巴氏涂片检测在基于异常组织病理学结果的 HIV 感染和未感染妇女的初级和连续分流宫颈筛查中更准确。